FirstImpact: Exclusive live event - survey feedback from breast cancer specialists

Exclusive to FirstWord Pharma PLUS subscribers - register  for our live presentation on Thursday (October 29) of findings from a survey of 120 oncologists evaluating how new clinical data will shape the treatment of triple-negative and adjuvant HR+/HER2- breast cancer.

_______________

Questions asked to breast cancer specialists from US, France, Germany and UK:

  • Did you attend the recent virtual ESMO 2020 congress?
  • Approximately what percentage of patients with previously untreated metastatic triple negative breast cancer (TNBC) do you test for PD-L1 status?
  • Approximately what percentage of these patients do you subsequently treat with the combination of Tecentriq (atezolizumab) and nab-paclitaxel?
  • Do negative data from the IMPassion131 study presented at ESMO 2020 make you more cautious about prescribing the approved combination of Tecentriq (atezolizumab) and nab-paclitaxel?
  • How compelling do you find the final overall survival (OS) analysis of the Phase III IMpassion130 study, evaluating Tecentriq in combination with nab-paclitaxel, compared with placebo plus nab-paclitaxel?
  • How compelling a treatment option will Keytruda plus investigator’s choice of chemotherapy become for metastatic TNBC patients whose tumours express PD-L1 with a Combined Positive Score (CPS) of ≥10?
  • Do you anticipate that approval of Keytruda (pembrolizumab) for the treatment of metastatic triple-negative breast cancer (TNBC) will drive an increase in PD-L1 testing?
  • To what approximately what percentage of patients do you anticipate prescribing Tecentriq plus Abraxane and Keytruda plus chemotherapy to 12 months’ after the latter’s regulatory approval?
  • How compelling a potential future treatment option do you consider the combination of Tecentriq (atezolizumab) with neo-adjuvant chemotherapy to be in this setting based on new data?
  • How will you prescribe Tecentriq and/or Keytruda based regimens in this setting?
  • Approximately what percentage of patients diagnosed with early (stage I-III) triple negative breast cancer would you consider candidates for treatment with either of these regimens?
  • Approximately what percentage of patients with metastatic triple-negative breast cancer receives a second and/or third-line treatment?
  • Have you already prescribed Trodelvy for the third-line treatment of metastatic triple negative breast cancer, following its accelerated approval by the FDA in April?
  • How compelling is new data for Trodelvy from the confirmatory Phase III ASCENT study presented at the recent virtual ESMO 2020 congress?
  • How compelling is new data from the Phase III monarchE study showing that the CDK4/6 inhibitor Verzenio in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence?
  • Approximately what percentage of patients diagnosed with invasive early stage disease fit the criteria of the monarchE study?
  • To what percentage of eligible patients meeting these criteria would you consider prescribing Verzenio?
  • Based on these data would you consider treating patients with early stage disease identified as being at a lower risk of relapse with Verzenio?
  • Will findings from the negative PALLAS study have any impact on your use of Ibrance for the approved setting for treatment of metastatic HR-positive, HER2-negative breast cancer?

_______________

To help FirstWord Pharma PLUS subscribers better understand how recent developments will impact the use of these therapies we will be presenting findings from a survey of 120 oncologists at an exclusive FW Live: FirstImpact event next Thursday (October 29). Please click here to register if you are a FirstWord Pharma Plus user or here to find out how to become a FirstWord Pharma PLUS subscriber.

FirstImpact is the newest addition to our Insight, Analysis and Views content offering FirstWord Pharma PLUS subscribers access each year to up to a dozen live events where our analysts present analysis of breakthrough clinical data based on physician surveys. It changes the game in pharmaceutical market news, providing industry professionals with superior analyses of the most important and disruptive clinical catalysts from the unique vantage point of prescribers.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more Physician Views articles, click here.